Topical diclofenac formulations for musculoskeletal pain
Topical diclofenac is recommended as first-line pharmacologic therapy for acute musculoskeletal pain (non–low back) and for selected patients with osteoarthritis (OA) with pain at joint sites amenable to topical treatment. [1], [2]
Strength meaning (1% vs 3%)
“1% diclofenac gel” refers to diclofenac sodium topical gel at 1% strength and is labeled in the United States for arthritis-related pain due to osteoarthritis at joint sites amenable to topical therapy (hand and knee in the common US OTC/labeling context). [3]
“3% diclofenac gel” in the United States refers to diclofenac sodium topical gel at 3% strength and is labeled for treatment of actinic keratosis (a dermatologic condition), not musculoskeletal pain. [4]
Key difference relevant to choosing for musculoskeletal pain
For musculoskeletal pain, selection should be limited to diclofenac topical products with an indication for OA or musculoskeletal pain, since the labeled indication for 3% diclofenac gel is actinic keratosis. [4]
Selection algorithm for musculoskeletal pain
Topical diclofenac should be selected based on the pain condition and the labeled indication.
- Osteoarthritis at a joint site amenable to topical therapy: topical NSAID use is appropriate, with diclofenac topical gel commonly used in guideline-directed OA care. [2]
- Acute pain from non–low back musculoskeletal injuries: topical NSAIDs with or without menthol gel are recommended as first-line therapy. [1]
- Skin conditions such as actinic keratosis: diclofenac 3% gel is labeled for actinic keratosis. [4]
Treatment initiation thresholds and expected onset
Topical NSAIDs are recommended as first-line therapy for acute non–low back musculoskeletal injuries to reduce pain and improve function. [1]
Dosing and product-use differences
Diclofenac 1% topical gel (OTC arthritis pain formulation) is applied up to 4 times daily to the affected area, with maximum daily dosing limits based on total grams per day and measurement using an included dosing card for the correct amount per application. [5]
Diclofenac 3% gel labeling is directed to actinic keratosis treatment rather than musculoskeletal pain, so dosing for musculoskeletal pain should not be inferred from dermatologic labeling. [4]
Common pitfalls to avoid
- Using diclofenac 3% gel for musculoskeletal pain based on strength alone is a labeling mismatch because 3% diclofenac gel is indicated for actinic keratosis. [4]
- Selecting a topical NSAID without checking that the product is labeled for the intended musculoskeletal indication risks lack of indication-concordant use. [4]
Targets and goals of therapy
Topical NSAID therapy for acute musculoskeletal pain is aimed at symptom reduction, improvement in physical function, and improved treatment satisfaction. [1]
Topical NSAIDs for OA are used to reduce pain at joint sites amenable to topical treatment as part of OA pharmacologic management. [2]